Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 19/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 19/20 | 0.44 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.37 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.37 |
| ▸ | IARS2 | Q9NSE4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5485682 | 0.99 | CHRNA7 (0.45) | CHRNA7KCNH2CHRNA1CYP3A4CYP2D6 | |
| SCHEMBL5477866 | 0.93 | CHRNA7 (0.42) | CHRNA7KCNH2CHRNA1CYP3A4CHRNB2 | |
| SCHEMBL5486394 | 0.88 | CHRNA7 (0.46) | CHRNA7KCNH2CHRNA1CYP3A4CYP2D6 | |
| SCHEMBL5483264 | 0.85 | MAP2K1 (0.46) | CYP3A4MAP2K2MAP2K1PRKCZIARS2 | |
| SCHEMBL5478055 | 0.83 | MAP2K1 (0.38) | CHRNA7CYP3A4MAP2K2MAP2K1PRKCZ | |
| SCHEMBL6205441 | 0.82 | CHRNA7 (0.46) | CHRNA7KCNH2CHRNA1CYP3A4CYP2D6 | |
| SCHEMBL5479864 | 0.80 | MAP2K1 (0.45) | MAP2K2MAP2K1PRKCZIARS2 | |
| SCHEMBL5477603 | 0.80 | MAP2K1 (0.41) | MAP2K2MAP2K1PRKCZIARS2 | |
| SCHEMBL5480959 | 0.80 | TUBB4A (0.41) | MAP2K2MAP2K1PRKCZIARS2 | |
| SCHEMBL5478784 | 0.79 | MAP2K1 (0.44) | MAP2K2MAP2K1PRKCZIARS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103121996-A | Novel heteroaryl-substituted arylaminopyridine derivatives as mek inhibitors | SERONO LAB | 2013-05-29 | — | — | CN | claimed |
| US-8076486-B2 | Heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO S.A. (CH) | 2011-12-13 | — | — | US | disclosed |
| US-8076486-B2 | Heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO S.A. (CH) | 2011-12-13 | — | — | US | disclosed |
| US-8076486-B2 | Heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO S.A. (CH) | 2011-12-13 | — | — | US | disclosed |
| US-20070287737-A1 | Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO SA (CH) | 2007-12-13 | — | — | US | disclosed |
| US-20070287737-A1 | Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO SA (CH) | 2007-12-13 | — | — | US | disclosed |
| US-20070287737-A1 | Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | MERCK SERONO SA (CH) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287737-A1 | Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors | NRAS, MAP3K5, MAP3K1 | CHRNA7 4850/4885KCNH2 3657/4885CHRNA1 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.